Login to Your Account


ISA Moving HPV Vaccine into Phase II with $10.5M Round

By Cormac Sheridan
Staff Writer

Wednesday, January 9, 2013
ISA Pharmaceuticals BV raised €8 million (US$10.5 million) in an internal financing round to fund a Phase II trial of its therapeutic vaccine for cervical cancer, ISA-HPV.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription


»

Our address has changed:
BioWorld | 115 Perimeter Center Place
Suite: 1100 | Atlanta, Georgia 30346, USA
 
For Sales Inquiries:
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Fax: 1-770-810-3145
BioWorld.salessupport@thomsonreuters.com
 
Privacy Policy | Terms of Use
 
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
BioWorld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2013 Thomson Reuters. Reproduction, reposting content is strictly prohibited.

Free Ezine

Sign up for Highlights FREE e-mail newsletter

Click here